Board of Directors
Arthur Mikaelian, Ph.D.
Chairman & CEO
One of Dr. Arthur Mikaelian’s greatest scientific contributions and groundbreaking inventions is Quantum Physics and Quantum Biology-based polarization technology, which targets molecular structure of the main ingredients in synthetic medications or natural compounds, leading to the increased potency of liquid and solid compounds, which substantially increases their therapeutic effectiveness. Dr. Mikaelian’s polarization technology has been awarded U.S. Patent 8,097,284B2 as it pertains to the Polarized Scorpion Venom solution. For the past 20 years, Dr. Mikaelian has been independently actively studying stress hormones (cortisol, epinephrine), and the master gene’s (ATF3) indirect influence on cancer cell activity and tumor progression. His initial findings quickly led him to the innovative creation of a new generation of pharmaceutical and nutraceuticals drugs, as well as expanding his interests in cancer and oncology.
Dr. Mikaelian’s education began in 1984 at the 2nd Medical Institute of Moscow and continued at the Vernadsky University of Biosphere Knowledge in Moscow, where he earned his doctorate in Biological/NeuroPsychology; he then went on to complete his postdoctoral work at Vernadsky. Dr. Mikaelian has broad experience with Quantum Physic and Quantum Biology. He also earned an MBA from the University of Bologna in Italy.
Executive Vice President
In 2013, Mr. Grant Mikaelian began working for an advanced biopharmaceutical company called Medolife. During his employment, he amassed a wide range of skills through managing various departments of the company. As a Marketing Sales Department Manager, he led many successful projects to improve customer experience through website development and design, enhanced customer support, streamlined ordering systems, configuration of B2C/B2B logistics, company rebranding, and preparation of marketing literature and presentations. He was later promoted to Operations Manager, overseeing and optimizing company departments on a larger scale. He was involved in production planning, project management of short and long-term goals, hiring prospective employees and contractors, corporate IT improvements, equipment procurement, international product registrations, due diligence preparation, and financial audits. He came to inspire confidence and began working closely with Dr. Arthur Mikaelian, CEO of Medolife. Soon after, Mr. Mikaelian was further promoted to Chief Business Development Officer. As the CBDO, he worked with existing and potential shareholders, was involved in domestic and international investment opportunities, managed multiple departments, increased company and product awareness, expanded product distribution channels, drafted Press Releases and articles, edited and proofread company literature, and more. Mr. Mikaelian is an organized leader with broad experiences in management and promotion of corporate growth.
Khalid Matalka, Ph.D., SI(ASCP)
Chief Scientific Officer
Professor Khalid Matalka received his BSc and MSc in Medical Technology in 1986 and 1988 from Yarmouk University, Jordan, and the University of Wisconsin-Milwaukee, USA. Then he received his Ph.D. in Pathology (Immunology and Cancer therapy) from Ohio State University, USA, in 1992. After finishing his Ph.D., Dr. Matalka joined Harvard Medical School as a Postdoctoral fellow till 1994. He is an American Board Certified as a Specialist in Immunology (SI-ASCP) and a member at the American Society for Cancer Research since 1994.
Dr. Matalka enrolled in academia as an assistant professor in 1995, then promoted to associate and then a professor in 2004. Prof. Matalka held a dean position at two different academic institutions. Besides, Prof. Matalka was a consultant for twenty years to a JPM pharmaceutical company and a hospital diagnostic laboratory. During those 22 years, Prof. Matalka was heavily involved in research mainly on immunomodulation, cancer research, and development of immunological assays. In 2016, he joined a pharmaceutical startup company named OncoTherapeutica, MA as a Chief Biologist. While there, Prof. Matalka was developing new potential drugs for the treatment of prostate cancer and melanoma. In March 2020, Prof. Matalka joined Medolife Corporation as Chief Scientific Officer (CSO) and, in February 2021, became the CSO of the newly established Medolife Rx.
Prof. Matalka has 65 publications in peer-reviewed international journals, and he is an Associate Editor of two and a member of the editorial board of several international journals. Prof. Matalka is known as an international reviewer in the fields of Cancer therapy, Immunomodulation, and Ethnopharmacology.